

Test Ref

Lab Ref.

Patient Name

Physician Name

VIBHAV MOHAN

Patient ID


Gender

Date of Birth

Test Date


Blood Sample Date

TEST SCORES




FIBROSIS

0.27
F2
advanced fibrosis



ACTIVITY

0.12
A0
no activity



STEATOSIS

0.15
S0
no steatosis (<5%)

INTERPRETATION

S0-A0-F2

Your result for the SAF score is S0-A0-F2. This score indicates that you have no steatosis (<5%), no activity and advanced fibrosis. Consult your physician for further evaluation.

BIOMARKER VALUES

Age: Height: Weight: BMI:

	Result	Unit		Result	Unit
Alpha2 Macroglobulin	1.62	g/L	ALT	14.1	IU/L
Haptoglobin	169	mg/dL	AST	15.2	IU/L
Apolipoprotein A1	133	mg/dL	Fasting Glucose	92.9	mg/dL
Total Bilirubin	0.4	mg/dL	Total Cholesterol	216	mg/dL
GGT	43.8	IU/L	Triglycerides	75.3	mg/dL

* NOTE: The highlighted value is at the extremes of the acceptable range of biomarker values.

The performance characteristics of this test were determined by Fibronostics US Inc. This test is not FDA approved/cleared. It is mandatory that interpretation of the results be performed in the clinical context by a physician. The testing should be deferred in medical conditions that could interfere with the inputs. The reliability of the value inputs is ensured by the lab in compliance with analytical and regulatory requirements. Any warning of extreme value inputs should lead to caution in interpreting the results. When difference in staging is observed with liver biopsy, it is recommended to be evaluated by the physician.

Fibronostics US Inc. | 274 E. Eau Gallie Blvd., #346 Indian Harbour Beach, FL 32937, USA | Tel: 888-552-1603 | Fax: 321-256-6061 | MedicalAffairs@fibronostics.com

WHAT LIVERFAST™ IS

LIVERFAST™ is a noninvasive panel of tests combining patients' age, gender and body mass index with 10 biological blood markers correlated with liver conditions, to generate 3 different scores for estimating 3 lesions: fibrosis, activity and steatosis.

For each lesion, LIVERFAST™ evaluates a quantitative score (0.00 to 1.00) and its estimated grade or stage, similar to the liver biopsy classification. LIVERFAST™ graphs display the calculated score and the estimated grade or stage with a color code (from green that signifies normal or early condition to red, a severe condition).

LIVERFAST™ algorithm was built according to the latest MASLD histopathologic scoring system for categorizing liver lesions, the SAF score*, that has two main advantages: to cover the entire spectrum of lesions (from S0A0F0 to S3A4F4) and to provide an activity score not biased by steatosis.

Liver damage (due to fibrosis, activity, steatosis) mainly due to metabolic syndrome risk factors (overweight, diabetes, excessive cholesterol, high blood pressure, etc.) or excessive alcohol intake can be improved by intensive lifestyle intervention (healthier lifestyle and/or reducing alcohol intake) and/or by drug treatment.


*Bedossa P. and al. Hepatology 2012;56:1751-9

HOW TO READ LIVERFAST™ RESULTS

Fibrosis is the progressive scarring of the liver leading to cirrhosis caused by the excessive accumulation of extracellular matrix, including collagen. Fibrosis could be reversible, more easily at early stages than late, and is mainly due to reaction from steatohepatitis (MASH)

Activity related to MASLD is the inflammation and ballooning (severe hepatic cell injury) that occurs in the liver tissue which leads to steatohepatitis (MASH). MASH activity can be reversed.

Steatosis is the accumulation of excessive fat (triglycerides) inside hepatocytes (liver cells). Steatosis is a reversible condition even at later stages.



NOTE: For readability, all score values shown are rounded to two significant digits – in boundary cases, where rounding suggests ambiguity, the stage rating should be considered as authoritative as the basis for interpretation. Graphs shown above are using sample data and are not based on the current patient's results.

The performance characteristics of this test were determined by Fibronostics US Inc. This test is not FDA approved/cleared. It is mandatory that interpretation of the results be performed in the clinical context by a physician. The testing should be deferred in medical conditions that could interfere with the inputs. The reliability of the value inputs is ensured by the lab in compliance with analytical and regulatory requirements. Any warning of extreme value inputs should lead to caution in interpreting the results. When difference in staging is observed with liver biopsy, it is recommended to be evaluated by the physician.

Fibronostics US Inc. | 274 E. Eau Gallie Blvd., #346 Indian Harbour Beach, FL 32937, USA | Tel: 888-552-1603 | Fax: 321-256-6061 | MedicalAffairs@fibronostics.com